The anti-parkinsonian drug zonisamide reduces neuroinflammation: Role of microglial Na_v 1.6.

ABSTRACT: Parkinson's disease (PD), the second most common age-related progressive neurodegenerative disorder, is characterized by dopamine depletion and the loss of dopaminergic (DA) neurons with accompanying neuroinflammation. Zonisamide is an-anti-convulsant drug that has recently been shown to improve clinical symptoms of PD through its inhibition of monoamine oxidase B (MAO-B). However, zonisamide has additional targets, including voltage-gated sodium channels (Na_v), which may contribute to its reported neuroprotective role in preclinical models of PD. Here, we report that Na_v1.6 is highly expressed in microglia of post-mortem PD brain and of mice treated with the parkinsonism-inducing neurotoxin MPTP. Administration of zonisamide (20 mg/kg, i.p. every 4 h × 3) following a

SUBMITTER: Hossain MM 

PROVIDER: S-EPMC7404626 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature